Stimulation of interleukin-1 β production may be involved in unresponsiveness to erythropoietin therapy

International Journal of Artificial Organs

Volumn 19, Issue 11, 1996, Pages 633-637

  Takemasa, A ^a   Yorioka, Noriaki ^a   Yamakido, M ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS; PATIENT TREATMENT; BLOOD;

CELL-BE; CELL/B.E; CELL/BE; CYTOKINES; HUMAN ERYTHROPOIETIN; INTERLEUKIN 1Β; INTERLEUKIN1; PERIPHERAL BLOOD MONONUCLEAR CELLS; PERITONEAL DIALYSIS; RENAL ANEMIA; ERYTHROPOIETIN; RESPONSE TO ERYTHROPOIETIN THERAPY;

BLOOD; DIALYSIS;

ERYTHROPOIETIN; INTERLEUKIN 1BETA; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONONUCLEAR CELL;

EID: 0030470406     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889601901103     Document Type: Article

References (20)

1. Schooley JC, Kullgren B, Allison AC. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible rote in the pathogenesis of hypoplastic anaemias. Br J Haematol 1987; 67: 11-7.
2. Maury CPJ. Anaemia in rheumatoid arthritis: role of cytokines. Scand J Rheum 1989; 18: 3-5.
3. 2+ and 1.25-dihydroxyvitamin D3 regulate the response to human recombinant erythropoietin in uremia: in vitro and in vivo studies In: Pagel H, Weiss C, Jelkmann W, eds. Pathophysiology and pharmacology of erythropoietin. Berlin: Springer, 1992; 165-9.
4. Kooistra MP, Struyvenberg A, van Es A. The response to recombinant human erythropoitein in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 127-8 (letter).
5. Bechensteen A, Halvorsen S. Insulin-like growth factor 1 and erythropoiesis during growth. In: Pagel H, Weiss C, Jelkmann W, eds. Pathophysiology and pharmacology of erythropoietin. Berlin: Springer, 1992: 89-96.
6. Brunati C, Cappellini MD, De Feo T, et al. Circulating burst-forming-unit erythroid and the responsiveness to recombinant human erythropoietin in patients on regular hemodialytic treatment. Nephron 1992; 62; 150-4.
7. Buemi M, Allegra A, Aloisi C, Privitera M, Morabito N, Frisina N. Influence of the treatment with recombinant human erythropoietin on plasma concentration of interleukin-1-alpha and tumour necrosis factor-alpha in hemodialyzed subjects. Nephron 1993; 64: 333-4 (letter).
8. Takemasa A, Yorioka N, Ito T, Yamashita K, Oda H, Yamakido M. Recombinant human erythropoietin increases interleukin-1 β production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy. Nephron 1994; 67: 245-7 (letter).
9. Johnson CS, Keckler DJ, Topper MI, Braunschweiger PG, Furmanski P. In vivo hematopoietic effects of recombinant interleukin-1α in mice: stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin. Blood 1989; 73: 678-83.
10. Kaltwasser JP. Disturbances of iron metabolism in the ane mia of chronic disorders. In: Bauer C, Koch KM, Scigalla P, Wieczorek L, eds. Erythropoietin: molecular physiology and clinical applications. New York: Marcel Dekker, Inc., 1993; 189-210.
11. Akahane K, Hosoi T, Urabe A, Kawakami M, Takaku F. Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells. Int J Cell Cloning 1987; 5: 16-26.
12. Clibon U, Bonewald L, Caro J, Roodman GD. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo. Exp Hematol 1990; 18: 438-41.
13. Johnson RA, Waddelow TA, Caro J, Oliff A, Roodman GD. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropotesis in nude mice. Blood 1989; 74: 130-8.
14. Buck M, Sherwin SA, Rosenblum M, Gutterman J. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 1987; 47: 2986-9.
15. Mamus SW, Beck-Schroeder S, Zanjani ED. Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes. J Clin Invest 1985; 75: 1496-503.
16. Jelkmann W, Fandrey J, Pagel H. Effects of inflammatory cytokines on the production of erythropoietin. In: Pagel H, Weiss C, Jelkmann W, eds. Pathophysiology and pharmacology of erythropoietin. Berlin: Springer, 1992; 263-9.
17. Stockenhuber F, Kurz RW, Geissler K, et al. Recombinant human erythropoietin activates a broad spectrum of progenitor cells. Kidney Int 1990; 37: 150-6.
18. Takeuchi M, Inoue N, Strickland TW, et al. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells. Proc Natl Acad Sci USA 1989; 86: 7819-22.
19. 125I-KRN5702 after a single intravenous dose in rats. Clin Report 1988; 22: 415-34 (in Japanese).
20. Lamperi S, Carozzi S, Nasini MG, Cantaluppi A, Salit M. Dyserythropoietic abnormalities in hemodialysis patients on long-term therapy with human recombinant erythropoietin. In: Pagel H, Weiss C, Jelkmann W. eds. Pathophysiology and pharmacology of erythropoietin. Berlin: Springer, 1992; 171-6.